Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TOSCA, thanks for posting. Pfizer and the Crazy 8 (Daiichi Sankyo, AstraZeneca, Sanofi-Aventis, Novartis, Johnson & Johnson, Bayer, Boehringer Ingelheim, AMGEN). Which one of the nine companies most desperately need Vascepa would most likely be Amarin's BO parner, if any.
I agree with your opinion. The majority of Amarin employees might have the working culture/altitude of workers at the DMV or post office, thanks to JT, IMO.
"lowball offer"? Not according to Nsleven.
No, only Germany scripts will show up in the next 12 months. The other EU countries take 12 months to negotiate a price.
chas, welcome back. Were you on Vascepa? If not, V should help your recovery according to Cardio-Link.
raf, I'll be disappointed if KM respond to your email directly. He has more important and urgent tasks to deal with as we speak. Blame JT for the Amarin culture he built during the last decade.
jasbg, which deal among those listed in your attached table was the last $25B single-drug BO? TIA.
one, I thought Eliquis is a joint partnership product between PFE and BMS and it didn't involve a BO.
Please email Amarin.
Never.
"25b"? Pop quiz, when was the last $25B single drug BO? Answer in 15 minutes.
The thing is, on 9/21/2018, we didn't even know the RIT results would come on the morning of 9/24/2018.
bfost, thanks for posting. I love the part of "fasting triglyceride levels > 135 mg/dL". Hikma and Dr. Reddy should be jumping for joy about this, though they might need to increase their reserve for paying any potential infringement damage down the road.
liz, thanks for the info. which correlates with pdudes post about PFE hitting a patent wall with another cardio drug they are currently marketing in Canada. Anbody remember the name of that cardio drug? I don't understand why that particular drug will run into the patent wall in Canada only and not in the US? I'll apreciate if anybody has the answer.
Web, then you should buy AMRN stocks all day long if you are that confident about V's therapeutic prowess.
Based on my math, total Q3 2021 scripts should still exceed Q2 2021 script level given current weekly script tragetory.
"PFE ain't getting my shares for anything less than $40."? Do you want to keep your AMRN shares as souvenir?
AMRN underperforms IBB, which is dragged down by a weak general market, today. However, if IBB were stronger today, AMRN would have dropped less. Everyday is different. For today, there are more AMRN sellers than AMRN buyers.
Pdude, thanks for posting. That's why AMRN's Research Department under the leadership of Steve ketchum who is under the management of moron JT should be shameful of themselves. JT could have been all over covid research using their only molecule they know.
What's the difference in scope between the potential good news on Sunday and the good news already reported last year in that Canadian trial, Cardiac-Link which I might have misspelled? If it's more or less the same, then the stock price most likely won't gain any traction next Monday.
Weak IBB dragging down AMRN.
Unusally high pre-market volume of 160K shares and a big bid of over 100K shares at $5.92.The key support is $5.75. It has to hold to continue the uptrend.
AMRN up close to 50% since KM took office three weeks ago. Just think about that for a moment.
Generics selling GV would welcome the potenetial Alzheimer indication in 2030.
BBI, the study completion date is Jan 31, 2023:
https://clinicaltrials.gov/ct2/show/NCT02719327
Generics got V for free while some AMRN shareholders want $15B ($35/sh) from BP. Money doesn't grow on trees.
liz, PFE approval for what? Why PFE need V? TIA.
I started my 401K and IRA contribututions (no Roth IRA yet in 1987) at the age of 22 right after college when I started my first job at Bell Lab in Holmdel, NJ despite having arrived at this country only four years earlier;
so it could be done and should be done.
Oldies but goodies, Pfizer takeover rumour ignites Amarin shares:
Pfizer is rumoured to be on the brink of a deal to acquire small biopharma Amarin in the wake of stellar data for its purified fish oil product Vascepa in cardiovascular disease prevention.
A StreetInsider report suggests it is preparing to put a bid in for Amarin, hoping to tap into a sales boost for Vascepa (icosapent ethyl) based on the REDUCE-IT trial, which found that the drug cut the risk of heart attacks and stroke by 25% in high-risk cardiovascular patients.
The results rivalled the efficacy seen in cardiovascular outcomes trials for Amgen’s PCSK9 antibody Repatha (evolocumab), and Vascepa’s relatively low cost and lack of side effects means it could become an attractive option for healthcare systems. Amarin is planning to file for approval to add the REDUCE-IT data to Vascepa’s label in the US this quarter, and has already started promoting the data with an upsized salesforce.
Neither company has commented on the rumour just yet. There has been speculation that Pfizer might be interested once again in a mega-merger deal like Takeda’s just-completed $62bn Shire acquisition and Bristol-Myers Squibb’s $74bn Celgene takeover, after failing to reach terms with AstraZeneca a few years ago.
http://www.pmlive.com/pharma_news/pfizer_takeover_rumour_ignites_amarin_shares_1274682
The fact that the Baker Brothers continue to hold 26.5 M shares of AMRN is underappreciated:
https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link
raf, you remind me of doctors who continue to prescribe L/GL despite relevant data for them not to.
Fill in the detail,
"The agreement will see at least 60 Pfizer representatives marketing Vascepa to between 6,000 and 10,000 family doctors in Canada (out of approximately 45,000), who are responsible for between 70 and 80 per cent of CV script volume within its target cohort, while HLS will continue to leverage its its in-house salesforce of roughly 30 people to market Vascepa to over 2,500 cardiologists and other specialists across Canada."
raf, can we borrow a page from countries which deal with covid successfully? We have racked up so much national debt to deal with covid and are still unsuccessful. Who is going to pay off those debt?
Thanks to LTRO who always makes information post:
HLS Therapeutics is a double, says Clarus Securities
https://www.cantechletter.com/2021/08/hls-therapeutics-is-a-double-says-clarus-securities/
The strategy is to start saving early and young in a Roth IRA account then you don't have to worry about Uncle SAM.
I believe Pfizer's new found vaccine wealth makes the company more aggressive and daring in acquisitions in order to set the company up for long term substainable growth.
The reason I posted the link is to show that PFE is still interested in statin add-on/cardiovascular market and if the Vupanorsen trial failed, PFE would definitely BO AMRN.
Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs),
https://www.prnewswire.com/news-releases/ionis-and-akcea-announce-that-pfizer-has-initiated-a-phase-2b-clinical-study-of-vupanorsen-akcea-angptl3-lrx-301166067.html
Great point. I think I have to google "pfizer primary detailed product".
liz, thanks for posting the reply from our Canadian friend. I like this part the most,
"Generally, a rep will be detailing several products at once; Vascepa will be the primary detailed product"